DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

March 25, 2015

Biomet, Incorporated
Ms. Amy Walriven
Manager, Regulatory Affairs
56 East Bell Drive
Warsaw, Indiana 46581

Re: K150503
Trade/Device Name: Echo Bi-Metric Microplasty Line Extension
Regulation Number: 21 CFR 888.3358
Regulation Name: Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis
Regulatory Class: Class II
Product Code: LPH, KWL, LZO, LWJ, KWZ, KWY, JDI, OQG, OQH, OQI, PBI
Dated: February 25, 2015
Received: February 26, 2015

Dear Ms. Amy Walriven:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing

(21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Lori A. Wiggins -S

for
Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below.

510(k) Number *(if known)*

K150503

Device Name
Echo Bi-Metric Microplasty Line Extension

Indications for Use *(Describe)*

1) Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
2) Rheumatoid arthritis.
3) Correction of functional deformity.
4) Treatment of non-union, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
5) Revision of previously failed total hip arthroplasty.

Porous coated components are intended for uncemented, biological fixation.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

In accordance with 21 CFR §807.92 and the Safe Medical Devices Act of 1990, the following information is provided for the Echo Bi-Metric Microplasty Line Extension 510(k) premarket notification.

Sponsor: Biomet Inc.
56 East Bell Drive
PO Box 587
Warsaw, IN 46581
Establishment Registration Number: 1825034

Contact: Amy L Walriven
Manager, Regulatory Affairs
Phone: (574) 372-6660
Fax: (574) 372-1683

Date: March 13, 2015

Subject Device:

Trade Name: Echo Bi-Metric Microplasty Hip System
Common Name: Hip Prosthesis
Product Code(s): LPH, LZO, KWZ, JDI, KWL, LWJ, KWY, OQG, OQH, OQI, PBI
Regulation/Description:

- 21 CFR 888.3358 – Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis
- 21 CFR 888.3353 – Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis
- 21 CFR 888.3310 – Hip joint metal/polymer constrained cemented or uncemented prosthesis
- 21 CFR 888.3350 – Hip joint metal/polymer semi-constrained cemented prosthesis
- 21 CFR 888.3360 – Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis
- 21 CFR 888.3390 – Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis

Legally marketed devices to which substantial equivalence is claimed:

- Echo Bi-Metric Microplasty Hip System (K143009)
- Balance Microplasty Hip System (K050251) - Reference

Device Description

The Echo Bi-Metric Microplasty Femoral Stem is a monolithic, collarless, straight stem designed to reduce hip pain for patients and restore joint biomechanics and stability. The femoral stem is designed to fit patient femoral anatomies for primary or revision hip arthroplasties. The stems

are manufactured from Ti-6Al-4V per ASTM F136/ASTM F620 and feature a proximal circumferential porous plasma spray (PPS) coating for biological fixation per ASTM F1580.

Patient contacting, reusable implant specific instruments are manufactured from stainless steel and include an aluminum titanium nitride (AlTiN) PVD or titanium nitride (TiN) PVD coating.

Intended Use and Indications for Use

1) Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
2) Rheumatoid arthritis.
3) Correction of functional deformity.
4) Treatment of non-union, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
5) Revision of previously failed total hip arthroplasty.

Porous coated components are intended for uncemented, biological fixation.

Summary of Technological Characteristics

The rationale for substantial equivalence is based on consideration of the following characteristics:

- **Intended Use:** The proposed and predicate Echo Bi-Metric Microplasty Femoral Stem devices have the identical intended use.
- **Indications for Use:** The proposed and predicate Echo Bi-Metric Microplasty Femoral Stem devices have identical indications for use.
- **Materials:** The proposed and predicate Echo Bi-Metric Microplasty Femoral Stem devices are manufactured from Ti-6Al-4V per ASTM F136 and ASTM F620 and feature a porous plasma spray (PPS) coating per ASTM F1580.
- **Design Features:** The proposed and predicate Echo Bi-Metric Microplasty Femoral Stem devices incorporate the same design features.
- **Sterilization:** The proposed and predicate Echo Bi-Metric Microplasty Femoral Stem devices are provided sterile via the same sterilization methods for single-use.

Summary of Performance Data

Results from mechanical tests demonstrate that the proposed Echo Bi-Metric Microplasty Femoral Stems are substantially equivalent to the predicate femoral stems. A description of the tests performed on the proposed device is as follows:

- Proximal Fatigue Testing – ISO 7206-6
- Distal Fatigue Testing – ISO 7206-4
- Range of Motion Analysis – ISO 21535

Substantial Equivalence Conclusion

The proposed Echo Bi-Metric Microplasty Femoral Stems have the same intended use and indications for use as the predicate devices. Performance test data demonstrates the device is as safe and effective and is substantially equivalent to the legally marketed predicate devices.